Marine Biomedical announces a strategic investment and commercial arrangement with Orthocell.

Marine Biomedical has entered into a strategic investment and commercial arrangement with Orthocell, strengthening the company’s position as it prepares to advance its first product, PearlBone™, toward market entry.

Under the agreement, Orthocell has made a $1 million strategic investment in Marine Biomedical and secured a First Right of Refusal (FROR) to commercialise Marine Biomedical’s products in the bone repair and regeneration field, on a product-by-product and territory-specific basis.

This investment builds on Marine Biomedical’s successful $2.1 million capital raise completed in May 2025, providing strong financial momentum as the company prepares to take PearlBone™, its first product, through initial regulatory approvals and commercial readiness activities toward market entry.

PearlBone™ is an innovative, next-generation bone substitute developed using sustainably sourced pearl shells from the West Australian Kimberley coast. Leveraging the natural properties of nacre, PearlBone™ has promising applications across orthopaedic, trauma and reconstructive surgery markets.

John Van Der Wielen, CEO of Orthocell, commented:

“Marine Biomedical has developed naturally derived, differentiated bone graft technology with strong scientific foundations and a compelling sustainability story. This investment and commercial arrangement provides Orthocell with the opportunity to evaluate PearlBone™ and future bone regenerative products as they progress toward commercialisation, aligned with our focus on regenerative medicine and global market expansion.”

Mal Di Giulo, Chairman of Marine Biomedical, said:

“This investment and associated commercial arrangements represent an important validation of Marine Biomedical’s technology platform and a strategic opportunity to leverage Orthocell’s scale, experience, and distribution capabilities as we prepare to progress PearlBone™ toward market across orthopaedic, trauma and reconstructive applications.”

Looking ahead, Marine Biomedical is building a scalable, sustainable biomaterials platform for bone repair and regeneration, with PearlBone™ representing the first step in a broader portfolio of next-generation products.